Praxis Precision Medicines (PRAX)
(Delayed Data from NSDQ)
$59.88 USD
+1.18 (2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $59.85 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Praxis Precision Medicines, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 81 | 100 | 276 | 297 | 45 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 10 | 12 | 6 | 1 |
Total Current Assets | 85 | 111 | 287 | 302 | 46 |
Net Property & Equipment | 1 | 1 | 1 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 1 |
Total Assets | 88 | 115 | 293 | 303 | 48 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 15 | 11 | 4 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 7 | 16 | 27 | 11 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 3 | 0 | 0 | 0 |
Total Current Liabilities | 16 | 34 | 38 | 16 | 7 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 2 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 121 |
Total Liabilities | 18 | 39 | 42 | 16 | 129 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 724 | 607 | 568 | 437 | 0 |
Retained Earnings | -654 | -531 | -317 | -150 | -81 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 70 | 76 | 251 | 287 | -81 |
Total Liabilities & Shareholder's Equity | 88 | 115 | 293 | 303 | 48 |
Total Common Equity | 70 | 76 | 251 | 287 | -81 |
Shares Outstanding | 8.70 | 3.10 | 2.90 | 2.50 | NA |
Book Value Per Share | 8.01 | 24.55 | 86.49 | 114.98 | 0.00 |
Fiscal Year End for Praxis Precision Medicines, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 352 | 207 | 81 | 101 | 124 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 4 | 4 | 2 | 6 |
Total Current Assets | 357 | 212 | 85 | 103 | 130 |
Net Property & Equipment | 0 | 0 | 1 | 1 | 1 |
Investments & Advances | 82 | 36 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 441 | 250 | 88 | 107 | 134 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 9 | 6 | 7 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 10 | 7 | 7 | 7 | 13 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 1 | 2 | 2 |
Total Current Liabilities | 21 | 19 | 16 | 17 | 24 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 1 | 2 | 2 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 22 | 21 | 18 | 20 | 28 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,145 | 923 | 724 | 714 | 708 |
Retained Earnings | -726 | -693 | -654 | -627 | -602 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 419 | 230 | 70 | 87 | 106 |
Total Liabilities & Shareholder's Equity | 441 | 250 | 88 | 107 | 134 |
Total Common Equity | 419 | 230 | 70 | 87 | 106 |
Shares Outstanding | 17.10 | 17.10 | 8.70 | 8.50 | 8.50 |
Book Value Per Share | 24.51 | 13.43 | 8.01 | 10.21 | 12.43 |